Deisenhammer F - Search Results

1

A comparative study of the relative bioavailability of different interferon beta preparations.

Deisenhammer F, Mayringer I, Harvey J, Dilitz E, Gasse T, Stadlbauer D, Reindl M, Berger T. Deisenhammer F, et al. Neurology. 2000 Jun 13;54(11):2055-60. doi: 10.1212/wnl.54.11.2055. Neurology. 2000. PMID: 10851362 Clinical Trial.

2

[Clinical aspects and diagnosis of multiple sclerosis].

Berger T, Deisenhammer F. Berger T, et al. Among authors: deisenhammer f. Wien Med Wochenschr. 1996;146(19-20):504-13. Wien Med Wochenschr. 1996. PMID: 9082650 Review. German.

3

Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies.

Deisenhammer F, Reindl M, Harvey J, Gasse T, Dilitz E, Berger T. Deisenhammer F, et al. Neurology. 1999 Apr 12;52(6):1239-43. doi: 10.1212/wnl.52.6.1239. Neurology. 1999. PMID: 10214750

4

Interferon-beta 1b augments activation-induced T-cell death in multiple sclerosis patients.

Kaser A, Deisenhammer F, Berger T, Tilg H. Kaser A, et al. Among authors: deisenhammer f. Lancet. 1999 Apr 24;353(9162):1413-4. doi: 10.1016/S0140-6736(99)00622-4. Lancet. 1999. PMID: 10227230 No abstract available.

5

Antibodies against the myelin oligodendrocyte glycoprotein and the myelin basic protein in multiple sclerosis and other neurological diseases: a comparative study.

Reindl M, Linington C, Brehm U, Egg R, Dilitz E, Deisenhammer F, Poewe W, Berger T. Reindl M, et al. Among authors: deisenhammer f. Brain. 1999 Nov;122 ( Pt 11):2047-56. doi: 10.1093/brain/122.11.2047. Brain. 1999. PMID: 10545390 Clinical Trial.

6

Vascular endothelial growth factor in CSF: a biological marker for carcinomatous meningitis.

Stockhammer G, Poewe W, Burgstaller S, Deisenhammer F, Muigg A, Kiechl S, Schmutzhard E, Maier H, Felber S, Schumacher P, Gunsilius E, Gastl G. Stockhammer G, et al. Among authors: deisenhammer f. Neurology. 2000 Apr 25;54(8):1670-6. doi: 10.1212/wnl.54.8.1670. Neurology. 2000. PMID: 10762512 Clinical Trial.

7

Immunoglobulin subclasses in patients with neutralizing and nonneutralizing antibodies against IFN-beta1b.

Deisenhammer F, Reindl M, Berger T. Deisenhammer F, et al. J Interferon Cytokine Res. 2001 Mar;21(3):167-71. doi: 10.1089/107999001750133195. J Interferon Cytokine Res. 2001. PMID: 11331039

8

Increased intrathecal production of apolipoprotein D in multiple sclerosis.

Reindl M, Knipping G, Wicher I, Dilitz E, Egg R, Deisenhammer F, Berger T. Reindl M, et al. Among authors: deisenhammer f. J Neuroimmunol. 2001 Oct 1;119(2):327-32. doi: 10.1016/s0165-5728(01)00378-2. J Neuroimmunol. 2001. PMID: 11585636

9

Anti-MOG and anti-MBP antibody subclasses in multiple sclerosis.

Egg R, Reindl M, Deisenhammer F, Linington C, Berger T. Egg R, et al. Among authors: deisenhammer f. Mult Scler. 2001 Oct;7(5):285-9. doi: 10.1177/135245850100700503. Mult Scler. 2001. PMID: 11724443

10

Non convulsive status epilepticus after replacement of valproate with lamotrigine.

Trinka E, Dilitz E, Unterberger I, Luef G, Deisenhammer F, Niedermüller U, Thaler C, Bauer G. Trinka E, et al. Among authors: deisenhammer f. J Neurol. 2002 Oct;249(10):1417-22. doi: 10.1007/s00415-002-0857-3. J Neurol. 2002. PMID: 12382160

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

257 results

Search Page

Filters